| Document |
Document Title |
|
WO/2007/033400A1 |
The invention generally provides a method of treating pain in a patient, the method comprising the step of administering to the patient, an effective dose of Methoxyflurane via an inhaler means. Preferably, the patient is a mammal. The p...
|
|
WO/2007/007057A1 |
Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents, formula (I): R1 represents: (a) -L-A or -...
|
|
WO/2007/006221A1 |
A synergistic time-delaying agent for local anesthetic. The said synergistic time-delaying agent contains dopamine 0.1-100mg, dexamethasone 1-200mg, compound vitamin B 0.5-20mg, metronidazole 10-400mg, berberine 10-1000mg, etamsylate 0.5...
|
|
WO/2006/127639A2 |
The preparation of an injectable solution of ropivacaine by dissolving ropivacaine base in aqueous acidic solution having a molar ratio of acid to ropivacaine base greater than 1:1 eliminates the need for a hydrochloride or hydrochloride...
|
|
WO/2006/124744A1 |
The present invention relates to bicyclic compounds of formula (I); wherein Z,RN,q,RM,Q,RQ are as defined in claim 1 , useful as inhibitors of ion channels.The invention also provides pharmaceutically acceptable compositions comprising t...
|
|
WO/2006/122462A1 |
A oral preparation comprising dyclonine hydrochloride for the endoscope examine in upper gastrointestinal tract is disclosed. The preparation has the effect of anaesthesia and lubrication. The preparation of the present invention especia...
|
|
WO/2006/122014A2 |
Bicyclic derivatives having formula (I) wherein Z, RN, B,q,Q and RQ are as defined in claim 1 and a composition thereof are useful as ion channel antagonists:
|
|
WO/2006/112276A1 |
A propofol-containing fat emulsion comprising 0.1 to 2 w/v% of propofol, 10 to 20 w/v% of an oily component and 2 to 5 w/v% of an emulsifying agent, the oily component being contained in an amount about 5 to 200 times the weight of the p...
|
|
WO/2006/096913A1 |
A method for providing anaesthesia to a subject having a wound, such as a laceration, a surgical incision, an ulcer, an abrasion or a burn, said method comprising the step of applying topically to the wound a composition comprising: at l...
|
|
WO/2006/089120A2 |
The present invention provides novel 2,6-diisopropyl phenol2,6-diisopropyl phenol analogs and sterile, stable pharmaceutical compositions of 2,6-diisopropyl phenol 2,6-diisopropyl phenol and analogs thereof useful as an antioxidant in th...
|
|
WO2006071995A9 |
The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, ...
|
|
WO/2006/069452A1 |
The invention relates to the use of a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan for producing an agent for treating pains.
|
|
WO/2006/069451A1 |
The invention relates to the use of resiniferatoxin (RTX) which is characterised by a formulation which does not contain a local anaesthetic and also, preferably, no other pharmacologically effective substances, for producing an agent fo...
|
|
WO/2006/071138A1 |
The invention relates to a tritium-traced syxitoxin dihydrichloride of formula (I) whose radioactivity ranges from 15-31 Ci/mmol and to a novel method for introducing tritium into a molecule comprising stages required for introducing tri...
|
|
WO/2006/066419A1 |
The invention relates to a mixture comprising a vanilloid receptor agonist and a substance inhibiting nerve regeneration. Said mixture is especially suitable as a painkiller.
|
|
WO/2006/067797A1 |
The invention provides a novel herbal formulation useful as local anesthetic in topical surgical operations, nerve block conduction, extradural and infiltration anesthesia. Formulation(s) comprises of extract(s) of Spilanthus calva and S...
|
|
WO/2006/034624A1 |
A process for preparing oil preparation of tetrodotoxin, characterized in that tetrodotoxin is dissolved with water or alcohol of acidity, and is prepared to the oil preparation with one (or more) surfactant (S) (or amphiphilicity lipid)...
|
|
WO/2006/031337A2 |
The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate &agr -secretase activity; improve or enhance cognitive ability; and/or reduce neurodegeneration in indivi...
|
|
WO/2006/017351A1 |
The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent di...
|
|
WO/2006/012700A1 |
The invention relates to a method of reducing or preventing pain associated with injection of an irritating substance comprising administering by injection, a combination of an effective amount of a local anaesthetic and an effective amo...
|
|
WO/2005/123728A1 |
This invention relates to novel 9-aza-bicyclo[3.3.1]nonane derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmac...
|
|
WO/2005/102365A1 |
A neurotransmission switching material comprised of an ester-bond-having polymeric compound; and a method of carrying out the on-off control of nervous action by the use of an ester-bond-having polymeric compound. Further, there are prov...
|
|
WO/2005/032520A1 |
Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the ...
|
|
WO/2005/032522A1 |
A stable topical aerosol foam is provided. The foam-forming formulation includes a HFA propellant and an active agent in an emulsion. The emulsion has an oil phase and an aqueous, i.e. water-containing, phase. The active agent may be pre...
|
|
WO/2005/032521A2 |
A topical liquid aerosol formulation for accurate metered dose delivery has been developed which includes a concentrate comprising a local anesthetic in a non-alcohol solvent and a hydrofluorocarbon (HFC) propellant. In the preferred emb...
|
|
WO/2005/032517A1 |
Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide diazepam for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the inve...
|
|
WO/2005/030700A2 |
Certain ß-amino acids that bind to the alpha-2-delta (a2S) subunit of a calcium channel are disclosed. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other d...
|
|
WO2003007875A9 |
The present invention relates to new analgesic, antipyretic and/or anti-inflammatory compounds represented by the general formula X - Y, in which X is a benzyl group, a saturated or unsaturated cycloalkyl group (I,II) or a non-cyclic, st...
|
|
WO/2005/009480A2 |
Genitourinary system disorders are treated with therapeutic agents, and optionally further with radiation treatments. One aspect of the invention provides a drug delivery device comprising a codrug or a pharmaceutically acceptable salt o...
|
|
WO/2005/009421A2 |
The invention relates to a novel use of 1-amino-alkylcyclohexane NMDA receptor antagonists such as neramexane in the treatment of pain hypersensitivity and neuropathic pain.
|
|
WO/2005/000287A1 |
External preparations for athlete's foot treatment capable of enhancing patient’s compliance and capable of reducing the symptom of rubefaction, comprising an anti-trichophyton drug mixed with at least one compound selected from among ...
|
|
WO/2004/110423A1 |
It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base...
|
|
WO/2004/108061A2 |
The present invention describes an injectable and stable pharmaceutical composition of thiopental ready-to-use, whose can be packed in glass ampoules for single doses or multidose vials for multiple doses. A method for stabilizing an aqu...
|
|
WO/2004/108113A1 |
A clear, stable , ready to use anaesthetic composition comprising 2,6 Diisopropylphenol (Propofol); at least one analgesic and like drug and antioxidants in a solvent system and a process for preparing the same. The said solvent system i...
|
|
WO/2004/103260A2 |
The present invention describes ternary and quaternary eutectic mixtures composed by active local anesthetic substances. These eutectic mixtures possess melting point inferior to 20°C and consist of homogeneous liquid useful in the prep...
|
|
WO/2004/101072A1 |
Methods and products for the attenuation or treatment of pain and the reduction of nociception are described. The methods and products are based on the modulation of CNS intracellular chloride levels. The methods and products may also re...
|
|
WO/2004/091636A1 |
According to the invention, there is provided a complex of a pharmaceutical compound selected from the group consisting of opioids, hormones, anaethetics and chemotherapeutic agents comprising the reaction product of: (a) one or more pho...
|
|
WO/2004/091589A1 |
An externally administerable agent, particularly a transdermal system for treating states of agitation or for use in preoperative sedation, contains, in an adhesive dressing preparation, a pharmaceutically effective amount of propofol (2...
|
|
WO/2004/092186A1 |
According to the invention, there is provided a phosphate derivative of a compound having a secondary hydroxy group. The compound having a secondary hydroxyl group may, for example, be chosen from pravastatin, atorvastatin venlafaxine, t...
|
|
WO/2004/092187A1 |
According to the invention, there is provided a phosphate derivative of a phenolic hydroxy compound comprising the reaction product of the following steps: (d) reacting the phenolic hydroxy compound with an alkyl &agr :&ohgr dialdehyde o...
|
|
WO/2004/089912A1 |
The present invention relates to novel benzimidazole derivatives of the formula (I) as defined in the description and in the claims, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compound...
|
|
WO/2004/087938A1 |
Novel substances PF1270A, PF1270B and PF1270C represented by the following formula (1) or pharmacologically acceptable salts thereof; a process for producing the same; and a pharmaceutical composition comprising at least one thereof as a...
|
|
WO/2004/082585A2 |
The present invention relates to conjugates of phenytoin with water-soluble polymers, having improved solubilityand absorption characteristics. Examples of polymers to.which phenytoin or a pro-drug thereof may be attached include natural...
|
|
WO/2004/074275A1 |
An indazolamide (I), wherein X, R1, R2, R3, R4, R5, R6, R7 and R8 have the meanings given in the description, and addition salts thereof with a pharmaceutically acceptable acid, a method for the preparation thereof and a pharmaceutical c...
|
|
WO/2004/064912A1 |
The invention relates to an otorhinological delivery device comprising at least one pharmaceutically active agent. According to the invention the device comprises a core comprising said at least one pharmaceutically active agent wherein ...
|
|
WO/2004/052337A2 |
The invention relates to a liquid or gaseous lipophilic substance exhibiting a pharmacological action and to the use thereof for preparing or producing an agent for introducing said lipophilic substance into a human body or an animal thr...
|
|
WO/2004/052354A1 |
A propofol-containing fat emulsion which comprises propofol, an oily component, and an emulsifier and further contains as the stabilizer, e.g., a prescribed amount of a phosphatidylglycerol whose constituent fatty acid components are spe...
|
|
WO/2004/052399A1 |
A composition for topical anesthesia which contains a topical anesthetic agent such as lidocaine hydrochloride serving as the active ingredient together with an anesthetic effect-persisting agent selected from the group comprising antihi...
|
|
WO/2004/047819A2 |
The present invention relates to methods of reducing the effects of neuropathically induced negative sensory phenomena (NSP). NSP are manifested as the decreased ability to feel light touch, pain, proprioception, vibration, warm/heat, an...
|
|
WO/2004/048332A1 |
A novel isoindoline compound represented by the formula (I). (I) The compound has sedative activity. The compound leads mammals to sedation and is hence useful as a narcotic drug.
|
